SML1569
Acotiamide dihydrochloride
≥98% (HPLC)
同義詞:
N-[2-[bis(1-Methylethyl)amino]ethyl]-2-[(2-hydroxy-4,5-dimethoxybenzoyl)amino]-4-Thiazolecarboxamide dihydrochloride, N-[2-[bis(1-Methylethyl)amino]ethyl]-2-[(2-hydroxy-4,5-dimethoxybenzoyl)amino]thiazole-4-carboxamide dihydrochloride, YM-443 dihydrochloride, Z-338 dihydrochloride
登入查看組織和合約定價
全部照片(1)
About This Item
經驗公式（希爾表示法）:
C21H30N4O5S · 2HCl
CAS號碼:
分子量：:
523.47
MDL號碼:
分類程式碼代碼:
12352200
NACRES:
NA.77
推薦產品
品質等級
化驗
≥98% (HPLC)
形狀
powder
儲存條件
desiccated
顏色
white to beige
溶解度
H2O: 20 mg/mL, clear
儲存溫度
−20°C
SMILES 字串
CC(C)N(C(C)C)CCNC(C1=CSC(NC(C2=CC(OC)=C(OC)C=C2O)=O)=N1)=O.Cl[H]
InChI
1S/C21H30N4O5S/c1-12(2)25(13(3)4)8-7-22-20(28)15-11-31-21(23-15)24-19(27)14-9-17(29-5)18(30-6)10-16(14)26/h9-13,26H,7-8H2,1-6H3,(H,22,28)(H,23,24,27)
InChI 密鑰
TWHZNAUBXFZMCA-UHFFFAOYSA-N
生化／生理作用
Acotiamide is a potent, selective and reversible inhibitor of human and canine stomach-derived acetylcholinesterase (AChE). Acotiamide showed no affinity for dopamine D2 or serotonin 5-HT4 receptors but does have activity as a muscarinic antagonist. It acts as a prokinetic drug through acetylcholinesterase inhibition and muscarinic receptor antagonism, and has been used for the treatment of functional dyspepsia (FD) involving gastric motility dysfunction.
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
K Ito et al.
Drug research, 66(4), 196-202 (2015-09-30)
Acotiamide is a first-in-class prokinetic drug approved in Japan for the treatment of functional dyspepsia. Given that acotiamide enhances gastric motility in conscious dogs and rats, we assessed the in vitro effects of this drug on the contraction of guinea
Norihisa Ishimura et al.
BMC gastroenterology, 15, 117-117 (2015-09-13)
The prevalence of gastroesophageal reflux disease (GERD) has been increasing worldwide, with proton pump inhibitor (PPI) administration the current mainstay therapy for affected individuals. However, PPI efficacy is insufficient especially for non-erosive reflux disease. Although it has been reported that
Alkesh V Zala et al.
Expert opinion on emerging drugs, 20(2), 221-233 (2015-02-04)
Functional dyspepsia (FD) is a relatively common gastrointestinal clinical condition that remains poorly understood. Controversies remain regarding the definition, pathophysiology and optimum treatment. The current treatment of FD is limited and no established regimen is available. Recent advances have improved
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務